Results 191 to 200 of about 28,272 (264)

Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]

Angiology, 2013
openaire   +5 more sources

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study. [PDF]

Front Endocrinol (Lausanne)
Wu JY, Lin YM, Hsu WH, Liu T, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.   +8 more
europepmc   +1 more source

Advances in Beyond Statin Lipid Therapies for ASCVD Risk Reduction. [PDF]

J Atheroscler Thromb
Shimabukuro M.
europepmc   +1 more source

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

, 2009
Joyce Chan, Derek E. Piper, Qiong Cao, Dongming Liu, Chadwick King, Wei Wang, Jie Tang, Qiang Liu, Jared Higbee, Zhen Xia, Yongmei Di, Susan Shetterly, Ziva Arimura, Heather Salomonis, William G. Romanow, Stephen T. Thibault, Richard Zhang, Ping Cao, Xiaoping Yang, Timothy Z. Yu, Mei Lü, Marc W. Retter, Gayle Kwon, Kirk R. Henne, Oscar Pan, Mei-Mei Tsai, Bryna Fuchslocher, Evelyn Yang, Lei Zhou, Ki Jeong Lee, Mark Daris, Jackie Sheng, Yan Wang, Wenyan Shen, Wen‐Chen Yeh, Maurice G. Emery, Nigel P.C. Walker, Bei Shan, Margrit Schwarz, Simon Jackson   +39 more
openalex   +2 more sources

Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries [PDF]

, 2019
Toshiyuki Nishikido, Kausik K. Ray
openalex   +1 more source

Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia [PDF]

, 2016
Nicola Ferri, Massimiliano Ruscica
openalex   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report [PDF]

, 2020
Junki Morino, Keiji Hirai, Shohei Kaneko, Saori Minato, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita   +15 more
openalex   +1 more source

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis. [PDF]

J Int Med Res
Yuan D, Cheng T, Cao Z, Wang F, Wang Y.
europepmc   +1 more source

A study of extended lipid profile in patients with acute coronary syndrome: Focus on Lipoprotein(a) and PCSK9. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Kumar P, Prajapathi S, Singh A, Pradhan A, Shukla A, Bhandari M, Sharma A, Vishwakarma P, Chaudhary G, Chandra S, Sethi R, Dwivedi S, Puri R.   +12 more
europepmc   +1 more source